Microfluidic trends in drug screening and drug delivery [PDF]
The low probability of a drug candidate's clinical success, the time consumed and the high cost of bringing a drug from concept to market emphasizes the need for new approaches to drug discovery. Recent innovations in microfluidic technologies, including
Feng, Jianguo +4 more
core +1 more source
Anti-Cancer Drug Screening with Microfluidic Technology [PDF]
The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in ...
Navid Kashaninejad +7 more
core +1 more source
Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. [PDF]
Sole reliance on one drug, Praziquantel, for treatment and control of schistosomiasis raises concerns about development of widespread resistance, prompting renewed interest in the discovery of new anthelmintics.
Bickle, Quentin D +46 more
core +3 more sources
Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. [PDF]
BACKGROUND: In view of the current widespread use of and reliance on a single schistosomicide, praziquantel, there is a pressing need to discover and develop alternative drugs for schistosomiasis.
Bickle, Quentin D +7 more
core +1 more source
Novel network pharmacology methods for drug mechanism of action identification, pre-clinical drug screening and drug repositioning [PDF]
The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Here we present two methodology innovations on network pharmacology modeling.
Jianghui Xiong
core +2 more sources
Drug-drug interactions in the hospital [PDF]
Introduction Drug interaction screening programs are an important tool to check prescriptions of multiple drugs for potential drug-drug interactions (pDDIs). Several programs are available on the market.
Vonbach, Priska
core +1 more source
Integrated dataset of screening hits against multiple neglected disease pathogens. [PDF]
New chemical entities are desperately needed that overcome the limitations of existing drugs for neglected diseases. Screening a diverse library of 10,000 drug-like compounds against 7 neglected disease pathogens resulted in an integrated dataset of 744 ...
Clive Yeates +78 more
core +1 more source
Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumour in the central nervous system (CNS). As the ideal targets for GBM treatment, Src family kinases (SFKs) have attracted much attention.
Lishun Zhang +11 more
doaj +1 more source
Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays [PDF]
Schistosomiasis is responsible for a tremendous public health burden, yet only a single drug, praziquantel, is available. New antischistosomal treatments should therefore be developed. The accuracy, speed and objectivity of in vitro drug screening depend
Gordana Panic +7 more
core +1 more source
Hypoglycemic effect of Camellia chrysantha extract on type 2 diabetic mice model
The aim of this study was to investigate the hypoglycemic effect of Camellia chrysantha using type 2 diabetic mice model. The ethyl acetate/dichloromethane extract exhibited the most effective hypoglycemic effect.
Lai Wang +4 more
doaj +1 more source

